<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02609048</url>
  </required_header>
  <id_info>
    <org_study_id>CB8025-21528</org_study_id>
    <nct_id>NCT02609048</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)</brief_title>
  <official_title>A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 12-week, double-blind, randomized, placebo-controlled, Phase 2 study, to evaluate the
      effects of two doses of seladelpar/MBX-8025 in subjects with Primary Biliary Cirrhosis (PBC)
      and an inadequate response to ursodeoxycholic acid (UDCA)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary:

      To evaluate the effect of MBX-8025 on Alkaline Phosphatase (AP) levels

      Secondary:

      To evaluate the safety and tolerability of MBX-8025 in subjects with Primary Biliary
      Cirrhosis (PBC) To evaluate the effects of MBX-8025 on Primary Biliary Cirrhosis (PBC)
      response criteria To evaluate the effects of MBX-8025 on other markers of liver function,
      lipids, pruritus and Quality of Life (QoL)

      Exploratory:

      To evaluate the effect of MBX-8025 on liver imaging and other biochemical markers that may be
      relevant to the pathophysiology of PBC or the mechanism of action of the drug
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped early after review of safety and efficacy demonstrated efficacy proof-of-concept
    and need for dose reduction.
  </why_stopped>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Alkaline Phosphatase (AP)</measure>
    <time_frame>12-Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of AP and Bilirubin</measure>
    <time_frame>12-Weeks</time_frame>
    <description>AP &lt; 1.67 × upper limit of normal (ULN) and Total Bilirubin within normal limit and
&gt; 15% decrease in AP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Aspartate aminotransferase (AST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Alanine aminotransferase (ALT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Gamma-glutamyl transferase (GGT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values</measure>
    <time_frame>12-Weeks</time_frame>
    <description>5'nucleotidase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Bilirubin (Total, Conjugated, Unconjugated)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Bone-specific AP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Triglycerides (TG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Total Cholesterol (TC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values</measure>
    <time_frame>12-Weeks</time_frame>
    <description>High Density Lipoprotein Cholesterol (HDL-C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Low Density Lipoprotein Cholesterol (LDL-C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC response criteria</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Paris I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC response criteria</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Paris II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC response criteria</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Toronto I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC response criteria</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Toronto II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC response criteria</measure>
    <time_frame>12-Weeks</time_frame>
    <description>United Kingdom (UK) UK-PBC risk score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5D-itch scale</measure>
    <time_frame>12-Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Score (VAS)</measure>
    <time_frame>12-Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBC-40 Quality of Life (QoL)</measure>
    <time_frame>12-Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Primary Biliary Cirrhosis (PBC)</condition>
  <arm_group>
    <arm_group_label>Placebo Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Capsule Two Capsules Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seladelpar / MBX-8025 50 mg Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBX-8025 50 mg capsule One Capsule Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seladelpar / MBX-8025 200 mg Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBX-8025 100 mg capsules (2 taken once daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Placebo Capsule (2 taken once daily)</description>
    <arm_group_label>Placebo Dose</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: Seladelpar / MBX-8025 50 mg</intervention_name>
    <description>MBX-8025 50 mg capsule (1 taken once daily)</description>
    <arm_group_label>Seladelpar / MBX-8025 50 mg Dose</arm_group_label>
    <other_name>MBX-8025 50 mg dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: Seladelpar / MBX-8025 200 mg</intervention_name>
    <description>MBX-8025 100 mg capsules (2 taken once daily)</description>
    <arm_group_label>Seladelpar / MBX-8025 200 mg Dose</arm_group_label>
    <other_name>MBX-8025 100 mg capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must have given written informed consent (signed and dated) and any authorizations
             required by local law

          2. 18 to 75 years old (inclusive)

          3. Male or female with a diagnosis of PBC, by at least two of the following criteria:

               -  History of AP above ULN for at least six months

               -  Positive Anti-Mitochondrial Antibodies (AMA) titers (&gt;1/40 on immunofluorescence
                  or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive
                  PBC-specific antinuclear antibodies

               -  Documented liver biopsy result consistent with PBC

          4. On a stable and recommended dose of UDCA for the past twelve months

          5. AP ≥ 1.67 × ULN

          6. For females of reproductive potential, use of at least one barrier contraceptive and a
             second effective birth control method during the study and for at least two weeks
             after the last dose. For male subjects, use of appropriate contraception (e.g.,
             condoms), so their female partners of reproductive potential do not become pregnant
             during the study and for at least two weeks after the last dose

        Exclusion Criteria:

          1. A medical condition, other than PBC, that in the investigator's opinion would preclude
             full participation in the study or confound its results (e.g., cancer on active
             treatment)

          2. AST or ALT &gt; 3 × ULN

          3. Total bilirubin &gt; 2 × ULN

          4. Auto-immune hepatitis

          5. Primary sclerosing cholangitis

          6. Known history of alpha-1-Antitrypsin deficiency

          7. Known history of chronic viral hepatitis

          8. Creatine kinase above ULN

          9. Serum creatinine above ULN

         10. For females, pregnancy or breast-feeding

         11. Use of colchicine, methotrexate, azathioprine, or systemic steroids in the two months
             preceding screening

         12. Current use of fibrates, including fenofibrates, or simvastatin

         13. Use of an experimental treatment for PBC

         14. Use of experimental or unapproved immunosuppressant

         15. Any other condition(s) that would compromise the safety of the subject or compromise
             the quality of the clinical study, as judged by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pol F Boudes, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>CymaBay Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami, Center for Liver Diseases</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norman Gitlin, MD</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Helathcare of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Hospital - Clinical Research Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Western Michigan, PLC, d.b.a. West Michigan Clinical Research</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Gastroenterology and Hepatology</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center / The Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore-Long Island Jewish Health System / Division of Gastroenterology</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai - The Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants for Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI St. Luke's Health Baylor College of Medicine Medical Center - Advanced Liver Therapies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Research Corporation at Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours St. Mary's Hospital of Richmond</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive and Liver Disease Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary Liver Unit (Heritage Medical Research Clinic)</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin - Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leber- und Studienzentrum am Checkpoint</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Carl Gustav Carus an der TU Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen, Zentrum fur Innere Medizin</name>
      <address>
        <city>Essen</city>
        <zip>45157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ifi-Studien und Projekte GmbH, A.d. Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Hamburg-Eppendorf MARTINISTRASSE 52</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Hochschule Hannover, Klinik fur Gastroenterologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitatsklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Gemeinschaftspraxis Herne</name>
      <address>
        <city>Herne</city>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKSH, Campus Kiel, Klinik fur Allgemeine Innere Medizin 1</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKSH, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig AOR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin der Johannes Gutenberg - Universitat Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Obserwacyjno-Zakazny im. Tadeusza w Bydgoszczy</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Krakow</city>
        <state>Malopolski</state>
        <zip>31-531</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii-Instytut Im. Marii Sklodowskiej-Curie</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP CSK im. Prof. K. Gibinskiego SUM w Katowicach</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Clinic Arkadiusz Pisula</name>
      <address>
        <city>Myslowice</city>
        <state>Slaskie</state>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <state>England</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull and East Yorkshire NHS Trust</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2jZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <disposition_first_submitted>January 23, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>January 23, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 26, 2018</disposition_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PBC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

